Intesa Sanpaolo Launches €30.6 Billion Bid for Monte dei Paschi to Drive Italian Banking Consolidation 
OpenAI Files Confidential IPO Draft as AI Giants Race Toward Public Markets 
Italy’s ITA Airways Weighs Legal Action Against Pratt & Whitney Over Grounded Airbus Fleet 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
Trump Administration Defends Anthropic AI Restrictions in Ongoing Federal Lawsuit 
Honda Leadership Crisis Deepens as Retired Executives Challenge CEO Toshihiro Mibe’s Strategy 
Naver Stock Jumps on NVIDIA Partnership to Build South Korea’s AI Infrastructure 
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil 
Jensen Huang Strengthens Nvidia’s South Korea Ties Amid AI Expansion 
RFK Jr. Spokesman Resigns Over Trump Administration’s Flavored E-Cigarette Policy 
CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak 
The four types of dementia most people don’t know exist 
RFK Jr. Faces Scrutiny Over David Geier’s HHS Role and Vaccine Review Work 
Trump Reportedly Approves Plan to Remove FDA Commissioner Marty Makary Amid Growing Controversies 
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern 
Shares of women’s healthcare company Organon & Co (NYSE: OGN) climbed sharply in after-hours trading on Thursday following reports that India-based Sun Pharmaceutical Industries Ltd. (NSE: SUN) is preparing a $13 billion acquisition offer. The news sparked strong investor interest, pushing Organon stock up as much as 8% to above $9.20 per share.
The surge comes despite Organon’s relatively modest market capitalization of $2.2 billion at the close of regular trading, highlighting the significant premium implied by the reported deal. According to sources cited by The Economic Times, Sun Pharma is planning to submit a binding all-cash offer, with financing reportedly backed by major global banks including JPMorgan, MUFG, and Citi.
The potential acquisition signals Sun Pharma’s strategic push to expand its footprint in the fast-growing women’s healthcare segment. Organon, a spin-off from Merck, specializes in reproductive health, biosimilars, and established medicines, making it an attractive target for global pharmaceutical companies seeking diversification and innovation in healthcare portfolios.
Reports also indicate that Sun Pharma intends to fully integrate Organon into its existing operations rather than issuing shares to Organon investors. This move suggests a long-term commitment to leveraging Organon’s capabilities, particularly its U.S.-based manufacturing infrastructure, which is considered a valuable asset in the pharmaceutical industry.
The deal has reportedly drawn competition from Germany’s Gruenthal, underscoring the increasing demand for companies focused on women’s health solutions. As pharmaceutical giants race to strengthen their pipelines and global reach, acquisitions like this could reshape the competitive landscape.
Investors and analysts are closely watching developments, as confirmation of the deal could significantly impact both companies’ valuations and the broader healthcare sector. The potential buyout highlights the growing importance of women’s health in global pharma strategies, while reinforcing Organon’s position as a key player in this specialized market.
